Suppr超能文献

治疗失眠症的处方药物与自杀企图风险:一项比较安全性研究。

Prescription Medications for the Treatment of Insomnia and Risk of Suicide Attempt: a Comparative Safety Study.

机构信息

Center of Excellence for Suicide Prevention, Canandaigua VA Medical Center, Canandaigua, NY, USA.

St John Fisher College, Wegnens School of Pharmacy, Rochester, NY, USA.

出版信息

J Gen Intern Med. 2019 Aug;34(8):1554-1563. doi: 10.1007/s11606-019-05030-6. Epub 2019 Jun 3.

Abstract

IMPORTANCE

Guidelines for the pharmacological treatment of chronic insomnia in adults recognize that trazodone and other off-label medications are commonly prescribed despite poor evidence. The Department of Veterans Health Affairs (VA) fills high volumes of inexpensive, over-the-counter sedating antihistamines and older antidepressants in addition to benzodiazepines and zolpidem. Yet little is known about the comparative safety of these agents with regard to suicidal behavior.

OBJECTIVES

To assess the comparative effectiveness of the safety of medications routinely used to treat insomnia in VA.

DESIGN

Comparative effectiveness using propensity score-matched samples.

SETTING

VA.

PARTICIPANTS

VA patients without any history of suicidal ideation or behavior 12 months prior to first exposure.

EXPOSURES

VA formularies and data were used to identify prescriptions for insomnia. Agents accounting for at least 1% of total insomnia fill volume were < 200 mg trazodone, hydroxyzine, diphenhydramine, zolpidem, lorazepam, diazepam, and temazepam. Exposure was defined as an incident monotherapy exposure preceded by 12 months without any insomnia medications. Subjects with insomnia polypharmacy or cross-overs in the 12 months following first exposure were excluded.

MAIN OUTCOMES AND MEASURES

Suicide attempts within 12 months of first exposure.

RESULTS

Three hundred forty-eight thousand four hundred forty-nine subjects met criteria and three well-balanced cohorts by drug class matched to zolpidem were created. After adjusting for days' supply, mental health history, and pain and central nervous system medication history, hazard ratios (compared to zolpidem) were as follows: (< 200 mg) trazodone (HR = 1.61, 95% CI 1.07-2.43); sedating antihistamines (HR = 1.37, 95% CI 0.90-2.07); and benzodiazepines (HR = 1.31, 95% CI 0.85-2.08).

CONCLUSIONS AND RELEVANCE

Compared to zolpidem, hazard of suicide attempt was 61% higher with trazodone (< 200 mg). No significant differences in suicide attempt risk were identified between benzodiazepines or sedating antihistamines and zolpidem, respectively. These findings provide the first comparative effectiveness evidence against the use of trazodone for insomnia.

摘要

重要性

成人慢性失眠的药理学治疗指南认识到,尽管证据不足,但曲唑酮和其他超适应证药物仍被广泛处方。美国退伍军人事务部(VA)除了开具苯二氮䓬类药物和唑吡坦外,还大量开廉价的、非处方镇静性抗组胺药和较老的抗抑郁药。然而,关于这些药物在自杀行为方面的相对安全性,人们知之甚少。

目的

评估 VA 常规用于治疗失眠的药物的相对安全性和有效性。

设计

采用倾向评分匹配样本的比较有效性研究。

设置

VA。

参与者

VA 患者在首次暴露前 12 个月内没有任何自杀意念或行为史。

暴露情况

VA 处方和数据用于确定失眠药物的处方。在总失眠药物使用量中占比至少为 1%的药物包括<200mg 曲唑酮、羟嗪、苯海拉明、唑吡坦、劳拉西泮、地西泮和替马西泮。暴露定义为在没有任何失眠药物治疗的情况下,首先使用单药治疗,持续 12 个月。在首次暴露后的 12 个月内有失眠药物联合用药或交叉用药的患者被排除在外。

主要结局和测量指标

首次暴露后 12 个月内的自杀企图。

结果

34.849 万名患者符合标准,并根据药物类别与唑吡坦匹配创建了三个均衡的队列。在调整了用药天数、精神病史、疼痛和中枢神经系统药物史后,与唑吡坦相比,风险比(HR)如下:(<200mg)曲唑酮(HR=1.61,95%CI 1.07-2.43);镇静性抗组胺药(HR=1.37,95%CI 0.90-2.07);和苯二氮䓬类药物(HR=1.31,95%CI 0.85-2.08)。

结论和相关性

与唑吡坦相比,曲唑酮(<200mg)的自杀企图风险增加了 61%。在苯二氮䓬类药物或镇静性抗组胺药与唑吡坦之间,自杀企图风险没有显著差异。这些发现为曲唑酮治疗失眠的相对有效性提供了首个证据。

相似文献

3
Associations between insomnia medications and risk of death by suicide.失眠药物与自杀死亡风险的关联。
Sleep Med. 2023 Nov;111:199-206. doi: 10.1016/j.sleep.2023.08.016. Epub 2023 Sep 19.

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验